SANOFI BELGIUM
ActiveSummary
SANOFI BELGIUM has been active since 1998 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €87.2m and a net result of €15.1m. Equity has been shrinking by about 6.6% per year since 2018. Its solvency ranks better than 44% of 6,167 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Overview
Official details
Source: KBO- Status
- Active since 27-10-1998 Normal situation
- Registered office
- 55 active companies are registered at this address 2 started in the 12 months before. Source: KBO register, as of 1 November 2026.
- Activity
- Wholesale of pharmaceutical and medical goods NACE 46460and 1 other
- Joint committee
- 200 Aanvullend Paritair Comité voor de bedienden · annual accounts 2023
- Establishment units
- 2.089.115.328 1831 Machelen (Brab.), since 05-11-1998
- 2.222.809.438 1000 Brussel, since 01-01-2005
- Financial year end
- 31 December
- Peppol
- Reachable since 25-11-2025
Board and ownership
- Bart VermeulenManaging director
- Hao ZhengDirector
- Auditor
- Ernst & Young
- Sanofi-Aventis Participations90%annual accounts 2025
- SANOFIconsolidatedLEI register
- Sanofi S.A.10%annual accounts 2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.4%
- Turnover
- €296.7m
- ▲ 7.8%
- Profit
- €15.1m
- ▼ 62.7%
- Equity
- €87.2m
- ▼ 12.0%
- Total assets
- €218.9m
- ▲ 26.1%
- Employees on 31-12-2025
- 189
- ▲ 1.6%
Score breakdownraises riskLiquidity: current ratio 1.70, cash €0, halved1 of the last 3 accounts latelowers riskFounded in 1998Size: turnover €296.7m, 185.5 FTE, total assets €218.9mShow the evidence
Checked score
About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, medium-sized). It does better than 50% of them on solvency, 20% on liquidity, 62% on profitability and 44% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 44 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Appointment: Hao Zheng (director)Resignation: Peter Oldenziel (director)
- · Gazette deed Appointment: Bart Vermeulen (director)Resignations: Johan Heylen (director) and Peter Verreth (director)
- · Gazette deed Appointment: FORVIS MAZARS Bedrijfsrevisoren (statutory auditor)
Comparable companies
These companies have the same main activity as SANOFI BELGIUM: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €83m and €400m, founded between 1984 and 1996.
| Company | Total assets | Turnover |
|---|---|---|
| SANOFI BELGIUM Machelen (Brab.) | €218.9m | €296.7m |
| NOVARTIS PHARMA Machelen (Brab.) | €168.8m | €378.6m |
| JOHNSON & JOHNSON MEDICAL Machelen (Brab.) | €225.6m | €330.0m |
| GC EUROPE Leuven | €107.3m | €209.0m |
| SIEMENS HEALTHCARE Dilbeek | €109.3m | €454.7m |
| ANSELL HEALTHCARE EUROPE Anderlecht | €400.0m | €472.7m |
| LIVLINA Sint-Niklaas | €82.9m | €278.3m |
Key facts about SANOFI BELGIUM
- What is the company number of SANOFI BELGIUM?
- The company number of SANOFI BELGIUM is 0464.435.901. The VAT number is the same number with BE in front: BE 0464.435.901.
- Where is SANOFI BELGIUM based?
- The registered office is at Leonardo da Vincilaan 19, 1831 Machelen (Brab.).Company details
- What does SANOFI BELGIUM do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of SANOFI BELGIUM?
- The legal form of SANOFI BELGIUM is Public limited company (NV).
- When was SANOFI BELGIUM founded?
- SANOFI BELGIUM was founded on 27-10-1998.
- Is SANOFI BELGIUM still active?
- Yes, SANOFI BELGIUM is an active enterprise in the KBO register.
- How many employees does SANOFI BELGIUM have?
- SANOFI BELGIUM had an average of 185.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does SANOFI BELGIUM fall under?
- In its 2023 annual accounts, SANOFI BELGIUM states joint committee 200 (Aanvullend Paritair Comité voor de bedienden).
- What is the turnover of SANOFI BELGIUM?
- The turnover of SANOFI BELGIUM was €296.7m in financial year 2025, according to the filed annual accounts.
- Is SANOFI BELGIUM profitable?
- In financial year 2025, SANOFI BELGIUM made a profit of €15.1m.
- Where can I find the annual accounts of SANOFI BELGIUM?
- SANOFI BELGIUM filed 27 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of SANOFI BELGIUM due?
- SANOFI BELGIUM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.